Dr Yacine Hadjiat is global head of Biogen Digital Health Solutions. He sat down with pharmaphorum at Frontiers Health 2022 in Milan to discuss how his group approaches digital innovation around ...

The stock’s performance has been below most large drugmakers’ performance. Biogen's revenues declined 3% in the first nine months of 2024. Sales of Biogen’s key multiple sclerosis (“MS ...

Biogen’s commitment to scientific innovation, quality, and patient-centered solutions underscores its position as a key player in advancing neuroscience and addressing the evolving needs of ...

Along with academic partners in the United States and Europe, Biogen has sponsored a technology-enabled solution, Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS).

(RTTNews) - Biogen Inc. (BIIB) announced Thursday that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) and the European Medicines ...

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA ...

Sage Therapeutics, Inc. (Nasdaq: SAGE) ("Sage" or "the Company"), today announced that its Board of Directors has initiated a process to explore strategic alternatives for the Company. The Board ...

Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business development deals, the company's CEO said. Biogen CEO sees no ...